Intensive Safety Monitoring of Rituximab (biosimilar Novex® and the Innovator) in Pediatric Patients with Complex Diseases
Frontiers in pharmacology(2022)
Key words
Rituximab,Biosimilar Pharmaceuticals,Monoclonal Antibody,Pediatric,Adverse Drug Reactions,Hypersensitivity,Risk Factors
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined